Prosecution Insights
Prosecution Insights
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (83%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, CHI TANG P | 1 | 80.8% | +24.8% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| KHAN, MEHMOOD B | 1 | 69.3% | +22.5% |
| WHITEMAN, BRIAN A | 1 | 68.3% | +16.7% |
| KEKIA, OMAR M | 1 | 67.3% | +22.5% |
| BARTON, JEFFREY THOMAS | 1 | 35.1% | +5.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18405181 | METHODS AND MODULES FOR QUALITY OF SERVICE PROVISIONING IN LINK ADAPTATION | CHENG, CHI TANG P | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288813 | METHODS FOR TREATMENT OF NEURON DEGENERATION | BRETZ, COREY LANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014322 | DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NONCODING RNAS AS TARGETS | WHITEMAN, BRIAN A | 61d |
| 18405181 | METHODS AND MODULES FOR QUALITY OF SERVICE PROVISIONING IN LINK ADAPTATION | CHENG, CHI TANG P | — |
| 18372419 | METHODS AND SYSTEM OF COLLABORATIVE LINK ADAPTATION | KHAN, MEHMOOD B | — |
| 17607849 | SOLID ELECTROLYTE MATERIAL FOR LITHIUM SECONDARY BATTERY, ELECTRODE, AND BATTERY | KEKIA, OMAR M | — |
| Art Unit | Apps |
|---|---|
| 2463 | 1 |
| 1658 | 1 |
| 2419 | 1 |
| 1636 | 1 |
| 1722 | 1 |
| 1726 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18405181 | METHODS AND MODULES FOR QUALITY OF SERVICE PROVISIONING IN LINK ADAPTATION | CHENG, CHI TANG P | 2463 | §103 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18288813 | METHODS FOR TREATMENT OF NEURON DEGENERATION | BRETZ, COREY LANE | 1658 | §103 | Non-Final OA | — | Pending | Oct 29, 2023 |
| 18372419 | METHODS AND SYSTEM OF COLLABORATIVE LINK ADAPTATION | KHAN, MEHMOOD B | 2419 | §103 | Final Rejection | — | Pending | Sep 25, 2023 |
| 18014322 | DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NONCODING RNAS AS TARGETS | WHITEMAN, BRIAN A | 1636 | DPOther | Non-Final OA | 61d | Pending | Jan 03, 2023 |
| 17607849 | SOLID ELECTROLYTE MATERIAL FOR LITHIUM SECONDARY BATTERY, ELECTRODE, AND BATTERY | KEKIA, OMAR M | 1722 | §103 | Final Rejection | — | Pending | Oct 29, 2021 |
| 17422789 | INORGANIC SULFIDE SOLID ELECTROLYTE HAVING HIGH AIR STABILITY, AND PREPARATION METHOD AND USE THEREOF | BARTON, JEFFREY THOMAS | 1726 | §103 | Final Rejection | — | Pending | Jul 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial